American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab for patients with myeloma with early or late relapse after initial therapy: Subgroup analysis of CASTOR and POLLUX
    Journal Article

    Spencer, A.; Moreau, P.; Mateos, M. V.; Goldschmidt, H.; Suzuki, K.; Levin, M. D.; Sonneveld, P.; Orlowski, R. Z.; Yoon, S. S.; Usmani, S. Z.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Establishing costs for commercial chimeric antigen receptor T-cell (tisagenlecleucel; kymriah) in children and young adult B-cell acute lymphoblastic leukemia; A merged analysis from the PRWCC and PHIS
    Meeting Abstract

    Satwani, P.; Chao, K.; Lopez-Garcia, M.; Hall, M.; Jin, Z.; Winestone, L. E.; Friedman, D. N.; Phelan, R.; Baggott, C.; John, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with accelerated/blast-phase MPNs that received allogeneic stem-cell transplant in the current era of myeloid therapies
    Meeting Abstract

    Patel, A. A.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Viswabandya, A.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Assessment of outcomes of consolidation therapy by number of cycles of blinatumomab received in newly diagnosed measurable residual disease negative patients with B-lineage acute lymphoblastic leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
    Meeting Abstract

    Luger, S. M.; Sun, Z.; Mattison, R. J.; Paietta, E.; Roberts, K. G.; Zhang, Y.; Racevckis, J.; Lazarus, H. M.; Rowe, J. M.; Arber, D. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Practice patterns of transplant centers regarding maintenance treatment post allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A survey on behalf of the EBMT Acute Leukemia Working Party
    Meeting Abstract

    Abou Dalle, I.; Labopin, M.; Khvedelidze, I.; Baron, F.; Brissot, E.; Bug, G.; Esteve, J.; Giebel, S.; Gorin, N. C.; Lanza, F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory follicular lymphoma: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Zinzani, P. L.; Wang, M. L.; Nasta, S. D.; Lech-Maranda, E.; Ogawa, Y.; Fakhri, B.; Kuss, B.; Miyashita, K.; Patel, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of a prognostic 23-gene expression panel in a set of 390 multiethnic Hodgkin lymphoma patients
    Meeting Abstract

    Colombo, A.; Wan, J. Y.; Jiang, A.; Aparicio, J.; Lam, E.; Aoki, T.; Song, J. Y.; Pullarkat, S.; Chao, C.; Mejia-Arangure, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Heterogeneity in access and toxicity management of commercially available BCMA-directed CAR-T and Bispecific T-cell engager therapy among the international myeloma community
    Meeting Abstract

    Hassan, H.; Samur, M. K.; Cohen, A. D.; Moreau, P.; Otero, P. R.; Kumar, S. K.; Mateos, M. V.; Avigan, D.; Sperling, A. S.; Nadeem, O.; more...
    Blood (2023)

    Fulltext@MSK | Save